新股消息 | 新济医药递表港交所 核心产品XJN010已于中国进入II期临床试验

Company Overview - Xinji Pharmaceutical, founded in 2007 and headquartered in Guangzhou, China, is an innovative pharmaceutical technology company in the clinical stage, developing two core technology platforms: soluble microneedle formulation technology and nasal inhalation formulation technology [3] - The first core product, dexmedetomidine hydrochloride microneedle patch, is designed for preoperative sedation in pediatric and adult patients, aiming to enhance patient comfort and clinical efficiency by providing a painless alternative to intravenous sedation [3] - The second core product, XJN010, is based on the nasal inhalation platform, intended for rapid drug delivery to the brain, bypassing the gastrointestinal tract and blood-brain barrier, particularly suitable for patients with sudden onset conditions [4] Financial Information - Research and development expenses for the fiscal years 2023, 2024, and the first half of 2025 were approximately RMB 18.43 million, RMB 16.41 million, and RMB 11.62 million respectively [5] - Revenue for the fiscal years 2023, 2024, and the first half of 2025 was approximately RMB 54.09 million, RMB 49.03 million, and RMB 28.14 million respectively [6] Industry Overview - The preoperative sedation market in China is expected to grow steadily, with the pediatric sedation patient population projected to increase from 9.06 million in 2020 to 10.23 million by 2032, reflecting a compound annual growth rate (CAGR) of 1.79% from 2028 to 2032 [8] - The overall market size for preoperative sedation in China was approximately RMB 7.36 billion in 2020, with expectations to exceed RMB 7.6 billion by 2024 and reach around RMB 8.24 billion by 2032, driven by increased surgical volumes and a growing demand for comfort-oriented medical services [12] - The global sedation market is also experiencing stable growth, with the market size projected to increase from USD 8.64 billion in 2020 to USD 10.39 billion by 2032, with pediatric sedation showing a higher growth rate compared to adult sedation [14]